Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
In This Article:
Argenx stock tumbled Thursday after the company's autoimmune disease drug, Vyvgart, beat first-quarter sales forecasts — but not by enough.
Terms and Privacy Policy